These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29428036)

  • 1. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
    Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
    Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative predictors for early recurrence of resectable pancreatic cancer.
    Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
    World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
    Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
    J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis.
    Asaoka T; Miyamoto A; Maeda S; Hama N; Tsujie M; Ikeda M; Sekimoto M; Nakamori S
    Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):75-80. PubMed ID: 29428109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
    Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
    World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
    Hosokawa Y; Nagakawa Y; Sahara Y; Takishita C; Katsumata K; Tsuchida A
    Dig Surg; 2017; 34(2):125-132. PubMed ID: 27658221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T; Zhang MG; Yu XJ; Liu L
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer.
    Sawayama H; Iwatsuki M; Kuroda D; Toihata T; Uchihara T; Koga Y; Yagi T; Kiyozumi Y; Eto T; Hiyoshi Y; Ishimoto T; Baba Y; Miyamoto Y; Yoshida N; Baba H
    Surg Today; 2018 Nov; 48(11):994-1003. PubMed ID: 29926189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
    Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
    World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of preoperative prognostic factors in patients with resectable invasive intraductal papillary mucinous carcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Surgery; 2020 Dec; 168(6):994-1002. PubMed ID: 32139141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
    Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
    Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection.
    Li J; Li Z; Kan H; Sun Z; Xing J; Cheng Y; Bai C
    Pancreatology; 2019 Mar; 19(2):302-306. PubMed ID: 30737189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.